An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbersarticle Published on 2023-05-222024-09-05 Journal: Translational Neurodegeneration [Category] update2024, [키워드] Granulocyte–macrophage colony-stimulating factor neuroprotection Parkinson’s disease regulatory T cells Sargramostim therapy Unified Parkinson’s Disease Rating Scale [DOI] 10.1186/s40035-023-00361-1 PMC 바로가기 [Article Type] article